CN Patent

CN111225688B — 靶向碳酸酐酶阳性癌症的基于fbsa的治疗和放射性成像缀合物

Assigned to Purdue Research Foundation · Expires 2025-06-17 · 1y expired

What this patent protects

本公开涉及碳酸酐酶IX抑制剂的组合物和方法。本公开还涉及碳酸酐酶IX抑制剂的靶向缀合物。本公开还涉及碳酸酐酶IX抑制剂的靶向缀合物在治疗疾病的方法和疾病成像的方法中的用途。

USPTO Abstract

本公开涉及碳酸酐酶IX抑制剂的组合物和方法。本公开还涉及碳酸酐酶IX抑制剂的靶向缀合物。本公开还涉及碳酸酐酶IX抑制剂的靶向缀合物在治疗疾病的方法和疾病成像的方法中的用途。

Drugs covered by this patent

lutetium-lu-177-vipivotide-tetraxetan (LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN)

Patent Metadata

Patent number: CN111225688B
Jurisdiction: CN
Classification: —
Expires: 2025-06-17
Drug substance claim: No
Drug product claim: No
Assignee: Purdue Research Foundation
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.